This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Labcorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.
IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.
What's in Store for Option Care Health (OPCH) in Q3 Earnings?
by Zacks Equity Research
Option Care Health's (OPCH) Q3 results are likely to be driven by sustained strong utilization.
Will Patient Volumes Aid Community Health's (CYH) Q3 Earnings?
by Zacks Equity Research
Community Health's (CYH) third-quarter results are likely to benefit from improved payer mix and growing surgery volumes, partly offset by a decline in patient days.
Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength
by Zacks Equity Research
Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.
InMode (INMD) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.
What's in Store for Canopy Growth (CGC) in Q1 Earnings?
by Zacks Equity Research
Strong demand for legal cannabis products in the Canadian recreational cannabis market and the launch of new products are expected to have driven Canopy Growth's (CGC) Q1 performance.
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure recovery in its legacy business in the second quarter.
Breast Health Arm to Boost Hologic (HOLX) in Q3 Earnings
by Zacks Equity Research
Hologic's (HOLX) Breast Health is likely to have driven Q3 performance, owing to strong performance from improved semiconductor chip availability and strong backlog.
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The growing adoption of Panther instruments and an expanded Panther installed base as well as strength in Breast Health is expected to have driven Hologic's (HOLX) Q3 revenues.
AmerisourceBergen Corporation (ABC) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AmerisourceBergen (ABC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Will Boston Scientific (BSX) Beat Q2 Earnings Estimates?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN and other interventional cardiology therapies.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Sales rebound in the base business for Diagnostics business and strong drug development orders are expected to have driven LabCorp's (LH) second-quarter performance.
What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Within the Transcatheter Aortic Valve Replacement (TAVR) arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in TAVR procedures globally.
5 Stocks to Buy From the Prospering Dental Supplies Industry
by Indrajit Bandyopadhyay
Here we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, ALGN, COO, XRAY and PDCO.
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL
by Zacks Equity Research
Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.
Veeva (VEEV) Falls Nearly 3% on Morgan Stanley Downgrade
by Zacks Equity Research
Veeva's (VEEV) shares lose nearly 3% after Morgan Stanley downgrades the stock to underweight, citing potential revenue loss from Salesforce's entry into the Life Sciences customer relationship management market.